Antiplatelet Therapy After Spontaneous Intracerebral Hemorrhage and Functional Outcomes. Issue 11 (November 2019)

• Record Type: Journal Article
• Authors: Murthy, Santosh B.; Biffi, Alessandro; Falcone, Guido J.; Sansing, Lauren H.; Torres Lopez, Victor; Navi, Babak B.; Roh, David J.; Mandava, Pitchaiah; Hanley, Daniel F.; Ziai, Wendy C.; Kamel, Hooman; Rosand, Jonathan; Sheth, Kevin N.; Butcher, K.; Davis, S.; Gregson, B.; Lees, K.R.; Lyden, P.; Mayer, S.; Muir, K.; Steiner, T.
• Is Part Of: Stroke. Volume 50:Issue 11(2019)
• Publication Date: 2019-11
• Subjects: cerebral hemorrhage -- mortality -- platelet aggregation inhibitors -- stroke; Cerebrovascular disease -- Periodicals; Cerebral circulation -- Periodicals; 616.81
• DOI: 10.1161/STROKEAHA.119.025972
• Languages: English
• ISSNs: 0039-2499

Abstract

Abstract : Background and Purpose—: Observational data suggest that antiplatelet therapy after intracerebral hemorrhage (ICH) alleviates thromboembolic risk without increasing the risk of recurrent ICH. Given the paucity of data on the relationship between antiplatelet therapy after ICH and functional outcomes, we aimed to study this association in a multicenter cohort. Methods—: We meta-analyzed data from (1) the Massachusetts General Hospital ICH registry (n=1854), (2) the Virtual International Stroke Trials Archive database (n=762), and (3) the Yale stroke registry (n=185). Our exposure was antiplatelet therapy after ICH, which was modeled as a time-varying covariate. Our primary outcomes were all-cause mortality and a composite of major disability or death (modified Rankin Scale score 4–6). We used Cox proportional regression analyses to estimate the hazard ratio of death or poor functional outcome as a function of antiplatelet therapy and random-effects meta-analysis to pool the estimated HRs across studies. Additional analyses stratified by hematoma location (lobar and deep ICH) were performed. Results—: We included a total of 2801 ICH patients, of whom 288 (10.3%) were started on antiplatelet medications after ICH. Median times to antiplatelet therapy ranged from 7 to 39 days. Antiplatelet therapy after ICH was not associated with mortality (hazard ratio, 0.85; 95% CI, 0.66–1.09), or death or major disability (hazard ratio, 0.83; 95% CI, 0.59–1.16) compared with patients not started on antiplatelet therapy. Similar results were obtained in additional analyses stratified by hematoma location. Conclusions—: Antiplatelet therapy after ICH appeared safe and was not associated with all-cause mortality or functional outcome, regardless of hematoma location. Randomized clinical trials are needed to determine the effects and harms of antiplatelet therapy after ICH. Abstract : Supplemental Digital Content is available in the text.